|1.||Banerjee, Subhashis: 2 articles (10/2014 - 03/2012)|
|2.||Tang, Cheng-Cai: 1 article (10/2014)|
|3.||Tham, Lai-San: 1 article (10/2014)|
|4.||Satterwhite, Julie H: 1 article (10/2014)|
|5.||Cameron, Gregory S: 1 article (10/2014)|
|6.||Choi, Siak-Leng: 1 article (10/2014)|
|7.||Antoni, Christian: 1 article (04/2013)|
|8.||Kolbinger, Frank: 1 article (04/2013)|
|9.||Lee, David M: 1 article (04/2013)|
|10.||Patel, Dhavalkumar D: 1 article (04/2013)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
03/29/2012 - "We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment. "
10/01/2014 - "Ixekizumab (LY2439821), a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds and neutralizes interleukin (IL) 17A has demonstrated efficacy in the treatment of psoriasis. "
10/01/2012 - "Papp et al. (N Engl J Med 2012; 366: 1181-9) and Leonardi et al. (N Engl J Med 2012; 366: 1190-9) respectively assessed the efficacy and safety of brodalumab (AMG 827), a human monoclonal antibody directed against interleukin (IL)-17RA, the receptor of IL-17A and ixekizumab (LY2439821), a humanized anti-IL-17 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis. "
04/01/2010 - "LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study."
04/01/2010 - "We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized anti-interleukin-17 (anti-IL-17) monoclonal antibody, in a first in-human trial in rheumatoid arthritis (RA) patients taking oral disease-modifying antirheumatic drugs (DMARDs). "
07/01/2012 - "We examined skin lesions obtained from 40 subjects participating in a phase I, randomized, double-blind, placebo-controlled trial of the anti-IL-17 mAb ixekizumab (previously LY2439821) in which subjects received 5, 15, 50, or 150 mg of subcutaneous ixekizumab or placebo at weeks 0, 2, and 4. There were significant dose-dependent reductions from baseline in keratinocyte proliferation, hyperplasia, epidermal thickness, infiltration into the dermis and epidermis by T cells and dendritic cells, and keratinocyte expression of innate defense peptides at 2 weeks. "
|4.||Autoimmune Diseases (Autoimmune Disease)
04/01/2013 - "In conjunction with studies using the humanised anti-IL-17A monoclonal antibody (mAb) ixekizumab (LY2439821) and the fully human anti-IL-17RA mAb brodalumab (AMG 827), the findings on secukinumab provide evidence for the role of IL-17A in the pathophysiology of autoimmune disease and suggest the potential value of targeting this cytokine."
|1.||Antirheumatic Agents (DMARD)
|3.||Immunoglobulin G (IgG)
|4.||Interleukin-17 (Interleukin 27)
|6.||LY 165163 (PAPP)